Circulating Metabolites are Linked to Dementia and Brain Imaging Phenotypes, and Mediate Modifiable Risk Pathways

Yue Liu [1], Dorsa Abdolkarimi [1], Lachlan Gilchrist [1], Sara Calhas [1], Asger Wretlind [3,13], Latha Velayudhan [4], Nicholas J. Ashton [5,6,7,8], Henrik Zetterberg [5,9,10,11,12], Sheena Waters [1], Cristina Legido-Quigley [3,13*], Charles Marshall[1*], Petroula Proitsi[1,2*#]

[1] Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK

[2] Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK
[3] Institute of Pharmaceutical Sciences, King's College London, London, UK

[4] Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

[5] Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

[6] Wallenberg Centre for Molecular and Transla Medicine, University of Gothenburg, Gothenburg, Sweden.

[7] Department of Old Age Psychiatry, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
[8] NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.

[9] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Biskopsbogatan, Mölndal, Sweden.

[10] UK Dementia Research Institute at UCL, London, UK.

[11] Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

[12] Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.

[13] Steno Diabetes Center Copenhagen, Copenhagen, Denmark

[*]These authors jointly supervised this work: Cristina Legido-Quigley, Charles Marshall, Petroula Proitsi

[#]**Corresponding author**
Corresponding author's information:

Dr. Petroula Proitsi, PhD, Queen Mary University of London, Centre for Preventive Neurology, London, United Kingdom

E-mail: p.proitsi@qmul.ac.uk

1 **Abstract**

Dementia poses an escalating global health burden, yet its underlying mechanisms remain

incompletely understood. In this large-scale, targeted metabolomic study of UK Biobank

participants, we applied machine learning models to 327 metabolite and lipid particle

measures to identify metabolomic signatures predictive of incident all-cause dementia

(ACD), Alzheimer's disease (AD), and vascular dementia (VaD), beyond conventional risk

factors.

Metabolites within these signatures, including the linoleic acid to total fatty acids percentage

(LA_pct), glutamine, branched-chain amino acids (BCAAs), low-density lipoprotein (LDL)

size, small LDL phospholipids percentage (S_LDL_PL_pct) exhibited widespread

associations with dementia outcomes and with neuroimaging markers, including brain

atrophy and white matter hyperintensities (WMHs). Many of these key metabolites were

associated with plasma neurofilament light chain (NfL) and glial fibrillary acidic protein

(GFAP), and most were validated in an independent external cohort. Mediation analyses

highlighted that several metabolites potentially mediate the effects of modifiable risk

factors—such as obesity, diabetes, hypertension, and education—on dementia risk, with the

strongest mediating effects observed for LA_pct in the association between obesity and both

ACD and VaD.

Mendelian randomisation (MR) analyses suggested potential causal roles for several

metabolites, with the strongest associations being between glutamine and AD and between

LA_pct and white matter hyperintensity–related brain atrophy (WMH_atrophy), used as a

proxy for VaD. These findings were replicated for glutamine and partially for LA_pct using

instrumental variables (IVs) from larger Genome Wide Association studies. The LA_pct

associations extended to other polyunsaturated fatty acids (PUFAs), suggesting broader lipid

metabolic mechanisms contributing to WMH_atrophy. Statistical colocalisation and

expression quantitative trait loci (eQTL) integration revealed shared genetic loci between

glutamine, SPRY domain-containing protein 4 (SPRYD4) gene expression levels and AD,

and between LA_pct, fatty acid desaturase 1 (FADS1) gene expression levels and WMH-

related brain atrophy (WMH_atrophy). Mediation MR further highlighted potentially causal

mediating roles for these metabolites in the association between gene expression levels and

outcomes. Finally, multivariable MR (MVMR) indicated that glutamine partially mediates

the protective relationship between educational attainment and AD.

Overall, most MR associations aligned with neuroimaging-based associations, allowing
triangulation of evidence and strengthening causal inference. These findings highlight that
blood metabolites -particularly glutamine and LA_pct and other PUFAs- could potentially
present as promising biomarkers for early dementia detection and suggest links between
modifiable lifestyle factors, metabolic dysfunction, and neurodegeneration, offering potential
avenues for targeted prevention in at-risk populations

Introduction

Dementia represents a growing global public health challenge due to its substantial societal
and economic burden [1]. The insidious onset and progressive nature of dementia often delay
diagnosis until irreversible neurodegeneration has occurred, thereby limiting the effectiveness
of available therapeutic interventions [2]. Although new disease-modifying drugs offer clinical
benefits in early-stage Alzheimer's disease (AD)—the most common form of dementia [3,4],
their effects remain modest, often accompanied by side effects, and typically exclude
individuals with co-existing conditions such as cerebrovascular disease. There is therefore an
urgent need to better understand the mechanisms underlying dementia and identify novel
therapeutic targets and preventive strategies.

Metabolomics—the study of small molecules with a role in metabolism—represents one
avenue that may give a deeper insight into the aetiology of different dementias. Blood
metabolites sit at the end of the systems biology pathway and represent effective intermediate
phenotypes to a given disease because of their proximity to the clinical endpoint [5].
Metabolites have been reported to interact with amyloid-beta (Aβ) accumulation, driving
neuroinflammation, oxidative stress, and tau pathology, contributing to a self-perpetuating
cycle of neurodegeneration [6]. As blood metabolites are potentially modifiable through diet,
drugs and lifestyle, and many of them can cross the blood-brain barrier, they can offer a
potential window into early neuropathological changes, making them valuable markers of
dementia-related biological processes and potential targets for prevention.

While previous studies, including ours [5,7-10], have reported associations between blood
metabolites and dementia risk, few have systematically investigated how metabolites relate to
the future risk of different dementia subtypes, while also accounting for the high
intercorrelation among metabolites. Moreover, the relationships between blood metabolites
and brain imaging phenotypes—which may reveal early molecular and physiological
pathways preceding dementia—remain largely underexplored. Finally, given the close links

between blood metabolites and several modifiable dementia risk factors, such as
cardiometabolic traits [11-15], elucidating the molecular mechanisms through which these risk
factors influence dementia risk, offers novel opportunities for prevention, particularly in
high-risk populations.

To address these gaps, we performed a large-scale, untargeted metabolomic analysis using
data from the UK Biobank to advance our understanding of metabolomic changes associated
with incident dementia. Our objectives were: (1) to identify sparse metabolomic signatures
associated with incident all-cause dementia (ACD), AD, and vascular dementia (VaD); (2) to
assess the associations between key dementia-related metabolites and neuroimaging-derived
phenotypes, including global and regional brain volumes, white matter hyperintensities and
brain age; and (3) to investigate the potential mediating roles of key metabolites in the
relationship between established modifiable risk factors and incident dementia. We employed
a triangulation approach, integrating observational analyses, including machine learning
models, with causal inference approaches, such Mendelian randomization (MR) and
statistical colocalisation, to strengthen the robustness of findings.

Methods

Study design and participants

The study was based on data from the UK Biobank study (project ID: 78867), a large-scale
prospective cohort study including approximately half a million participants aged 37 to
73 years and recruited from 22 centres across the United Kingdom between 2006 and 2010
[16]. All participants provided consent for researchers to access their national health-related
hospital and death records. Participant data includes sociodemographic characteristics,
lifestyle behaviours, environmental exposures, and health-related factors collected through a
combination of a touchscreen questionnaire and nurse-led verbal interviews. The workflow of
the study and the exclusion criteria for the participants are summarized in the **Figure 1.**

Nightingale Metabolomics

Metabolomics were quantified in a random subset of 274,351 UK Biobank participants using
nuclear magnetic resonance (NMR) spectroscopy conducted by Nightingale Health Ltd [17].
The dataset included multiple metabolic pathways and metabolites such as lipids (e.g.,
cholesterol and fatty acids), amino acids, glycolysis-related metabolites, ketone bodies, and
other small-molecule compounds. Detailed information on the assay platform and metabolite

quantification is available in the UK Biobank NMR metabolomics companion document

(https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/NMR_companion_phase2.pdf).

Metabolite measurements were normalized for known sources of technical variation using the

ukbnmr R package (https://github.com/sritchie73/ukbnmr/), adjusting a subset of 107 non-

derived metabolites for technical variation using robust linear regression and deriving the

remaining metabolite measurements post-adjustment. We derived additional metabolite ratios

not present in the original Nightingale data but suggested by the *ukbnmr* package authors as

having potential biological significance [18]. In total, 327 metabolite measurements (107 non-

derived metabolites, 61 composite metabolites, 81 metabolite ratios, and 76 *ukbnmr*-derived

metabolite ratios) were analysed in this study. 271,610 participants were left after excluding

participants with more than 20% of missing metabolites. Imputation was performed using the

K-nearest neighbour (KNN) clustering method. Metabolite outliers (values > four SDs from

the mean) were winsorised. Following imputation and winsorisation, a rank-based inverse-

normal transformation was applied to all metabolite measurements to approximate a standard

normal distribution prior to performing association analyses. The NMR metabolites list can

be found in **Supplementary Table 1**.

Outcomes

Dementia diagnoses in the UK Biobank dataset were ascertained based on records from

hospital inpatient and death registries. Hospital inpatient records were obtained from the

Hospital Episode Statistics for England, the Scottish Morbidity Record for Scotland, and the

Patient Episode Database for Wales. Death registry records were acquired from the National

Health Service Digital for England and Wales as well as the Information and Statistics

Division for Scotland. Furthermore, dementia diagnoses were also identified from primary

care data utilising disease codes. The diagnoses of dementia were recorded using the tenth

edition of the International Classification of Diseases (ICD) coding system. The complete list

of codes utilised in this study can be found in **Supplementary Table 2**. Incident dementia

events were defined as diagnoses made after the baseline. Participants were censored at the

date associated with the incidence of dementia, date of death, or last known follow-up,

whichever occurred first. The distribution of time-to-event was illustrated in **Supplementary**

Figure 1.

The Imaging-Derived Phenotypes (IDPs) for cortical and subcortical volumes were obtained

using FreeSurfer's aparc atlas (field ID = 192; 66 cortical regions) and ASEG atlas (field ID =

190; 33 subcortical regions). Details of the imaging protocol are available in the open-source

document   (https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/brain_mri.pdf).   Brain-

predicted age was generated from raw T1-weighted MRI scans using *brainageR* R package

(version 2) [19].

Assessment of covariables and dementia risk factors

The following lifestyle and health-related characteristics associated with dementia risk were

included as covariables in all analyses: age at baseline, sex (male/female), ethnicity (White,

Asian, Black, Other), recruitment centre (England, Wales, Scotland), and the Townsend

Deprivation Index—a measure of material deprivation based on income, employment status,

and access to services. The Townsend Index scores range from 0 to 1, with higher scores

indicating greater deprivation.

APOE ε4 carrier status was determined from genetic data and categorised into 3 groups: non-

carriers, carriers of one ε4 allele, and carriers of two ε4 alleles. Additional covariates,

included educational attainment (secondary vs. non-secondary education) which is an early-

life modifiable dementia risk factor suggested by Lancet commission [1] , as well as

cardiometabolic risk factors linked to blood metabolites[11-15]: smoking status (never, previous,

current), alcohol consumption (never, previous, current), obesity (BMI ≥ 30 kg/m²), and

history of diabetes and hypertension. Hypertension was defined as self-reported medication

use, prior diagnosis or a mean blood pressure of ≥140/90 mm Hg at baseline assessment.

Diabetes at baseline was assessed through self-reports or HbA1c concentrations≥6.5%

These were derived from self-report questionnaires, hospital episode statistics, and death

registry records. Detailed definitions and sources for all covariates are provided in

Supplementary Table 2.

Statistical analyses

<u>**Individual Cox Proportional Hazards Regressions**</u>

All investigated outcomes had enough events, meeting the rule-of-thumb requirement of at

least 10 events per variable in the model. To address potential inferential bias due to missing

covariate values, we performed imputation using KNN method. Cox proportional hazards

regression was used to assess the associations between individual blood metabolites and

incident dementia outcomes (ACD, VaD and AD). Participants were censored at the date

associated with the incidence of dementia, date of death, or last known follow-up. Hazard

ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated. We

evaluated the proportional hazards assumption using Schoenfeld residuals. We constructed

three models: Model 1 adjusted for age, age^2, sex, and their interaction terms (age∗sex,

age^2∗sex), recruitment centre, ethnicity, and Townsend deprivation index; Model 2

additionally adjusted for *APOE* ε4 carrier status; Model 3 further included modifiable risk

factors for dementia (education level, obesity, smoking status, alcohol intake, and histories of

diabetes and hypertension).

Interaction and subgroup analysis

167 To investigate whether sex and *APOE* ε4 carrier status modified the relationship between

168 metabolites and dementia outcomes, we investigated interactions between metabolites and

169 sex, and metabolites and *APOE* ε4 carrier status, as well as combined metabolites*sex*

170 *APOE* ε4 carrier status interactions. We further conducted subgroup analyses stratifying by

171 sex, *APOE* ε4 carrier status, and their combined categories.

Lasso-Regularised Cox Proportional Hazards Regression

To develop predictive models, we used the full dataset excluding participants with

neuroimaging data. The remaining dataset was then randomly partitioned using the *caret* R

package (version 6.0-94) [20] into training (50%), validation (25%), and test (25%) subsets,

with stratification to preserve the proportion of outcome classes across all splits. Metabolite

levels within each subset were inverse rank normalised separately. To identify important

metabolites, we applied 10-fold cross-validation with a fixed α of 1 (Lasso regression) to the

training data using the *glmnet* R package (Version 4.1-8) [21]. This process was repeated over

100 iterations. In each iteration, the optimal λ value was selected based on the cross-

validation results, and the corresponding regularised coefficients for each metabolite were

recorded. Metabolites were then ranked according to the mean absolute value of their

regularised coefficients across all iterations, reflecting their overall contribution to the model.

To determine the most predictive subset, we evaluated the C-index in the validation set by

sequentially adding the top-ranked metabolites in groups of five. The final set of top

metabolites was defined as the point at which adding additional metabolites no longer

resulted in a statistically significant improvement in the C-index using bootstrapping method.

These selected metabolites were used to construct a metabolomic risk score (MetRS) in the

test set to evaluate its predictive performance. (**Supplementary Figure 2**).

Incremental improvements in the C-index were evaluated by adding the MetRS to three
baseline models (Model 1, Model 2, and Model 3), which were the same as the individual
Cox regression models described above. We conducted survival analyses to evaluate the
predictive performance of the MetRS for dementia risk at 5-year, 10-year and 15-year
intervals. Participants were categorised into a high-risk group (top decile of MetRS) and a
reference group (remaining deciles). To flexibly model and visualise the dose-response
relationship between MetRS and dementia risk, we employed Cox proportional hazards
models incorporating restricted cubic splines with three knots.

Independent replication sample

The AddNeuroMed/Dementia Case Register (ANM/DCR) cohort was used as an independent
replication sample to validate the associations of key NMR metabolites with AD and with
plasma biomarkers of AD pathology, including neurofilament light (NfL) and glial fibrillary
acidic protein (GFAP). Peripheral GFAP and NfL are sensitive markers of neuroinflammation
and neuronal damage and are elevated in the preclinical phase of dementia. The ANM/DCR is
a multicentre European public-private consortium established to facilitate biomarker
discovery in Alzheimer's disease [22]. AD was diagnosed clinically according to the
NINCDS/ADRDA criteria for probable AD. MCI subjects fulfilled the diagnostic criteria for
MCI [23]: (1) memory complaint by patient, family, or physician; (2) normal activities of daily
living; (3) mini-mental state examination score (MMSE) range between 24 and 30; (4)
geriatric depression scale score less than or equal to 5; (5) clinical dementia rating scale
(CDR) score of 0.5; (6) absence of dementia according to the NINCDS-ADRDA criteria for
AD. Plasma analyses were performed on an HD-1 analyser (Quanterix, Lexington, MA) at
the Department of Psychiatry and Neurochemistry, University of Gothenburg. Commercially
available Simoa assays were used to quantify GFAP (GFAP Discovery, #102336). In-house
Simoa assays were used to quantify NfL [24].

Associations with Brain Imaging-Derived Phenotypes

Linear regression analyses were conducted in a subset of participants with neuroimaging data
(N = 28,068) to examine the associations between key metabolites from each of the three
dementia-specific metabolite signatures and neuroimaging markers. We applied three levels
of covariate adjustment, consistent with the individual Cox proportional hazards models, with
additional adjustment for brain scan centre, intracranial volume and the time interval between
baseline and brain scans.

Mediation analyses

Mediation analyses were performed to investigate whether metabolites identified in LASSO penalised regression models mediate the associations between modifiable risk factors and incident dementia, following the framework by Baron and Kenny [25]. Linear regression was used to estimate the association between each modifiable risk factor and each metabolite (path a). Cox proportional hazards models were applied to assess the association between each metabolite and incident dementia while adjusting for the corresponding risk factor (path b), and to estimate the direct effect of the risk factor on dementia conditional on the metabolite (path c'). The total effect of each risk factor on dementia (path c) was estimated using unadjusted Cox models. Indirect effects were estimated as the product of the coefficients from paths a and b, and the proportion mediated (prop.Med) was calculated as the ratio of the indirect effect to the total effect, with 95% confidence intervals derived from 1,000 bootstrap samples using the *boot* R package. Indirect effects and prop.Med were calculated only when both path a and path b showed statistically significant associations. Categorical variables, including smoking and alcohol consumption, were dichotomised (0 = never; 1 = former or current) to aid interpretation of mediation estimates. Three models were evaluated in the mediation analysis: Model 1 adjusted for age, sex, recruitment centre, Townsend deprivation index, and ethnicity; Model 2 additionally adjusted for *APOE* ε4 carrier status; and Model 3 further adjusted for all remaining modifiable risk factors.

Mendelian Randomization (MR) analyses

GWAS summary statistics

An overview of the genome-wide association study (GWAS) summary statistics used in this study is provided in the **Supplementary Table 3**. For AD, we utilised summary statistics that excluded proxy phenotyping based on family history from the UK Biobank, given prior evidence that such data can influence effect direction and bias downstream analyses [26]. Summary statistics for VaD and ACD were obtained from the FinnGen consortium (data freeze 10). The *APOE* locus (chr19:45,020,859-45,844,508, GRCh37) was excluded from the dementia GWAS due to its known pleiotropic effects on non-dementia conditions [27]. For metabolomic traits, we used publicly available summary statistics from a large-scale meta-analysis of nuclear magnetic resonance (NMR)-based GWAS, which included 233 metabolic traits and a combined sample size of 136,016 individuals [28].

GWAS summary statistics for dementia risk factors were obtained from established consortia.
Specifically, we retrieved data for body mass index (BMI; N = 806,834) from the GIANT
consortium [30] and educational attainment (EA) summary statistics from the EA4 GWAS
meta-analysis (excluding 23andMe) conducted by the Social Science Genetic Association
Consortium (SSGAC; N = 765,283) [31]. We also retrieved summary statistics for obesity from
UK Biobank [32]; systolic and diastolic blood pressure (SBP and DBP) from UK Biobank and
the International Consortium of Blood Pressure Genome-Wide Association Studies (ICBP) [33];
hypertension from a GWAS based on UK Biobank data[34]; smoking and alcohol consumption
from a meta-analysis of 60 cohorts [35]; and diabetes from 32 GWAS conducted in individuals
of European ancestry [36].

Prior to MR analysis, all summary statistics were QC'd using the *MungeSumstats* R package
in R (version 4.2.2). QC was performed with reference to dbSNP build 144 and the
BSgenome.Hsapiens.1000genomes.hs37d5 genome build provided through Bioconductor.
The preprocessing pipeline included imputation of missing rsIDs, exclusion of duplicate and
multi-allelic variants, and alignment of alleles to the reference genome, with appropriate
flipping of effect alleles and frequencies. For datasets provided in GRCh38 coordinates,
genomic positions were converted to GRCh37 (hg19) using the UCSC Genome Browser
chain file within *MungeSumstats*.

Metabolite instrument selection

Independent instrumental variables (IVs) were initially selected based on genome-wide
significance (p < 5 × 10□□) using clumping at an r² threshold of 0.001 within a 10,000 kb
window around the lead variant. Clumping was performed using the *ieugwasr* R package
(v0.1.4), PLINK (v1.9), and the European reference panel from the 1000 Genomes Project
Phase 3 (N = 503), restricting to variants with a minor allele frequency (MAF) > 0.01. For
exposures with fewer than five IVs at this threshold, a relaxed significance threshold (p < 5 ×
10□□) was applied, consistent with previous studies. Metabolites with fewer than five IVs at
p < 5 × 10□□ were excluded. When an IV was unavailable in the outcome dataset, a proxy
variant in high linkage disequilibrium (r² > 0.8) was identified using LDlink, prioritising
proxies with the highest r² and closest genomic distance. Exposure and outcome datasets
were harmonized to ensure alignment of effect alleles, and strand-ambiguous palindromic
variants with MAF > 0.42 were excluded. Instrument strength was assessed using the F-
statistic (F = β^2/SE²), and weak instruments (F < 10) were removed [9].

MR analyses

We conducted bidirectional MR analyses on the casual relationship between key metabolites
and dementia using inverse variance weighted MR (IVW-MR) with multiplicative random
effects [37]. We additionally examined WMHs and WMH-related brain atrophy
(WMHs_atrophy). WMHs, as the most prevalent form of cerebral small vessel disease, are an
established marker of dementia risk. Principal Component 1 (PC1), derived from the shared
variance of WMH and cortical thickness via PCA, loads positively on WMH and negatively
on cortical thickness, serving as an index of WMHs_atrophy, was included in our study as a
proxy of WMHs related VaD [38] since the VaD GWA sample size is relatively small. To assess
the robustness of primary analyses, several complementary sensitivity analyses were
performed using the weighted median, weighted mode, and MR-Egger regression with
bootstrapped standard error methods [39]. The weighted-median approach provides consistent
estimates as long as up to 50% of the information is derived from valid IVs[40]. Weighted-
mode provides robust estimates when the plurality of similar individual-instrument causal
effect estimates originates from valid instrumental variables, even if a significant portion of
them is invalid [41]. We calculated Cochran's IVW Q-values to identify potential heterogeneity
among SNPs included in each analysis. To assess horizontal pleiotropy, we employed MR-
Egger regression, wherein the deviation of the Egger intercept from zero was considered
significant ($P < 0.05$) indicative of the presence of horizontal pleiotropy [42]. We also examined
possible pleiotropy using the MR-PRESSO Global test with P values calculated according to
1,000 simulations [43]. If substantial global heterogeneity was detected, a local outlier test was
subsequently conducted to identify any outlier SNPs. Subsequently, the causal effect
estimates were reassessed after removing outliers. Metabolites passing sensitivity analyses
were further inspected using leave-one-out (LOO) analysis to assess whether causal estimates
were driven by the inclusion of a single influential variant. Metabolites that passed all
sensitivity criteria were used in subsequent causal mediation MR analysis by performing
Multivariable MR (MVMR). Significant MR associations were further validated using
metabolite GWAS data from the UK Biobank and the Estonian Biobank [29]. To avoid sample
overlap between GWAS of exposure and outcome, GWAS data from the Estonian Biobank
alone were used to replicate associations between metabolites and WMHs and
WMHs_atrophy, as these outcome datasets include UKB participants. In contrast, meta-
GWAS data were used to replicate associations between metabolites and dementia subtypes.

Further analysis of single instrument metabolites

Using LOO analysis, we identified IVs that substantially influenced the IVW-MR estimate when excluded, by rendering the IVW-MR result non-significant. For each of these IVs, we extracted genomic regions ±250 kb and performed statistical colocalisation for each metabolite-outcome pair. Regions of interest were harmonised to include only variants present in the reference panel. Colocalisation was performed with the coloc.abf function of the *COLOC* package [44] using default priors ($1 \times 10^{\square\square}$, $1 \times 10^{\square\square}$, $1 \times 10^{\square\square}$). A posterior probability for hypothesis 4 (PP.H4 ≥ 0.8) was taken as strong evidence of colocalisation, while PP.H4 ≥ 0.6 was considered suggestive. For regions showing colocalisation (including suggestive), we annotated genes corresponding to credible SNPs using the eQTLGen Consortium dataset. For each identified gene, we extracted cis-eQTLs from eQTLGen whole-blood summary statistics within the same ±250 kb window and repeated the colocalisation procedure to evaluate overlap between eQTLs, metabolites, and outcomes. Genes colocalising with both the metabolite and outcome in a given trait pair were then instrumented: independent variants for gene expression were extracted from eQTL summary statistics ($p \leq 5 \times 10^{\square\square}$; $r^2 \leq 0.001$; clumping window = 10,000 kb). These were used in IVW-MR to estimate the causal effect of gene expression on both outcome and exposure. When fewer than five SNPs remained after clumping, the wald ratio for the top eQTL was applied. Where gene expression levels showed a significant causal effect on both an outcome and a metabolite, we calculated the proportion mediated using the product of coefficients method as per previous analyses [45].

Causal Mediation Analysis

MVMR was employed to investigate potential causal mediation effects [5] and to triangulate the findings from mediation analyses based on observational data. Consistent with the criteria used in observational mediation analyses, evidence of an association between the exposure and mediator (path a), as well as between the mediator and outcome (path b), was first required based on univariable MR analyses. A total causal effect of the exposure on the outcome was not required, as this may be masked by opposing indirect effects via the mediator. We conducted the same MR sensitivity analyses as those performed in the primary MR analyses. MVMR analyses were conducted using the *MVMR* R package [46]. The indirect effect and proportion mediated were calculated using the delta method to derive confidence intervals.

349   All statistical tests were two-sided, with p-values < 0.05 considered statistically significant.

350   To account for multiple comparisons, p-values from fully adjusted models were corrected

351   using the false discovery rate (FDR) method.

Results

Cohort characteristics

Baseline demographics and health characteristics of participants, stratified by incident

dementia status, are summarized in **Supplementary Table 4**. Following the exclusion of

individuals with prevalent dementia at baseline, 269,284 participants were included in the

analysis including 264,047 controls, 5210 ACD patients, 2311 AD patients and 1213 VaD

patients. Compared to the control group, all dementia subtypes exhibited significantly older

age, a higher prevalence of *APOE* ε4 carrier status, lower attainment of secondary education,

higher Townsend deprivation index scores, increased smoking prevalence, reduced alcohol

consumption, and higher rates of hypertension and diabetes. Additionally, ACD and VaD **-** but

not AD patients **-** demonstrated a higher proportion of male participants and an increased

prevalence of obesity relative to controls.

Association of individual metabolites with incident dementia

All associations between individual metabolites and incident dementia outcomes are shown

in **Supplementary Figure 3** and **Supplementary Table 5**. We additionally investigated

associations with several metabolite percentages not previously reported, including the

percentage of free cholesterol (FC) and of cholesterol esters (CE) relative to total cholesterol

(TC). **For HDL particles,** a higher percentage of FC/TC in large and very large HDL

particles was associated with increased dementia risk, while a higher FC/TC in medium HDL

particles was inversely associated with dementia risk, particularly in models 1 and 2. **For**

LDL and VLDL, most FC/TC in these particles were positively associated with ACD and

AD risk, with the exception of small VLDL particles, which showed the opposite effect.

Additionally, FC/TC ratios in medium and large LDL particles were negatively associated

with VaD.

Overall, we observed that more metabolites were associated with VaD than with AD.

However, this number decreased substantially after accounting for modifiable risk factors.

(**Supplementary Figure 4 and Supplementary Table 5**).

Interaction Analysis of Sex, *APOE* ε4 Carrier Status, and Individual Metabolites in Relation to Incident Dementia

In interaction analyses, the protective effects of most metabolites on ACD were attenuated both in females and in *APOE* ε4 carriers (*pFDR* < 0.05 for interaction term) (**Supplementary Figure 5 and Supplementary Table 6**). On the other hand, for certain metabolites that were positively associated with ACD — such as total phospholipid proportion, HDL phospholipids, and omega-6 to PUFA ratios—these harmful associations were attenuated in females. We also observed that the protective effect of branched-chain amino acids (BCAAs) appeared to be amplified in *APOE* ε4 carriers, and the detrimental effects of TGs percentages across all lipoprotein types, as well as FC proportions in VLDL and XL-HDL and omega-6 to PUFA ratios, were reduced in *APOE* ε4 carriers. Subgroup analyses supported these interaction patterns.

For AD, the protective effects of cholesterol concentrations or ratios in non-HDL lipoproteins were generally attenuated in *APOE* ε4 carriers (**Supplementary Figure 6 and Supplementary Table 7**), while BCAAs showed stronger protective in carriers. Subgroup analyses supported these interaction patterns. For VaD, although several metabolites showed interactions with sex and *APOE* ε4, none survived correction for multiple testing (**Supplementary Figure 7 and Supplementary Table**). We finally observed significant positive three-way interactions, indicating that the associations of LA_pct and omega-6 with VaD were modified by both sex and *APOE* ε4 carrier status, with these metabolites showing a markedly stronger protective association with VaD in female *APOE* ε4 carriers compared with female non-carriers.

Metabolite Signatures for Dementia Prediction

After selecting top metabolites based on incremental improvements in the C-index (**Supplementary Figure 8**), a signature of 15 metabolites predicted ACD and AD, while a signature of 10 metabolites predicted VaD. The metabolomic ACD and AD signatures alone predicted ACD and AD with C-indices of 0.657, 0.655 respectively, while the VaD signature predicted VaD with a C-index of 0.683. The metabolomic signatures significantly improved dementia prediction beyond traditional risk factors including age, sex, *APOE* ε4 carrier status and other modifiable risk factors including education, smoking, alcohol, obesity, diabetes and hypertension. **(Figure 2).** An exception was observed for VaD, where the addition of the

MetRS did not statistically enhance predictive performance beyond conventional risk factors.
When we looked at how well these MetRS predicted dementia risk over time—specifically at
5-year, 10-year, and 15-year intervals (**Supplementary Figure 9**), the MetRS for ACD and
AD demonstrated strong predictive performance within the first 10 years. In contrast, the
MetRS for VaD showed meaningful predictive ability starting at 5 years, although this
association was not significant after adjusting for modifiable risk factors. We finally observed
a dose-response relationship between the MetRS and dementia risk, with higher MetRS levels
associated with increased risk of dementia (**Supplementary Figure 10**).

Overall, we observed both overlapping and distinct markers constituting the MetRS for
different dementia subtypes (**Figure 3**), with seven of them—leucine, glucose, β-
hydroxybutyrate, creatinine, histidine, albumin and LA_pct—being shared across all three
subtypes. Each dementia subtype had also unique markers. Triglycerides in large HDL
particles (L_HDL_TG), total Lipids in Chylomicrons and Extremely Large VLDL
(XXL_VLDL_L), and total BCAA were specific to ACD; citrate and valine were unique to
AD; and acetoacetate and LDL size unique to VaD.

Validation of Dementia-Related Metabolites in an Independent Cohort

In the independent ANM/DCR cohort, LA_pct showed significant positive associations with
both AD and MCI compared to controls (**Supplementary Figure 11**). Glutamine showed a
nominally positive and acetoacetate a nominally negative association. We further examined
the relationships between these metabolites and AD-related biomarkers (GFAP and NfL) in
both the UK Biobank and ANM/DCR cohorts. Notably, glucose, tyrosine, and BCAAs were
negatively associated with GFAP or NfL, whereas citrate, creatinine, and LA_pct were
positively associated with GFAP or NfL across both cohorts (**Supplementary Figure 11**).

Association between MetRS, key metabolites and brain imaging phenotypes

Overall, all three MetRSs (ACD, AD, and VaD) were significantly associated with older brain
age, reduced brain volumes and enlarged ventricles (**Figure 4**). With regards to regional brain
volumes, the VaD MetRS showed the broadest pattern of associations, including volume
reductions in the brainstem, cerebellum, and temporal lobes (excluding the medial temporal
lobe), greater than those observed for the AD MetRS (**Figure 5**). Univariable regression
analyses between key MetRSs metabolites highlighted that two metabolites—LA_pct and
glutamine—consistently emerged as protective markers, showing associations with larger

brain volumes, reduced ventricular volume, lower WMHs burden, and younger predicted
brain age. In contrast, the percentage of free cholesterol in medium VLDL particles
(M_VLDL_FC_pct_C) was inversely associated with brain volume and ventricular
enlargement (**Supplementary Figure 12**). Regional brain volume analysis showed that
LA_pct, glutamine and M_VLDL_FC_pct_C were significantly associated with most brain
regions, in line with their associations in global imaging phenotype.

MetRS and Key Metabolites Mediating the Association Between Modifiable Risk
Factors and Dementia Risk

The MetRSs for the three dementia types were used to assess their mediating roles in the
relationships between modifiable risk factors and dementia types. The associations between
education, diabetes, and hypertension and dementia risk were mediated by all three MetRSs
(**Supplementary Tables 9 and 10**). Notably, only the VaD MetRS mediated the relationship
between obesity and VaD. Among the top mediation effects (prop.Med >30%) observed in
model 1 were: Diabetes >> MetRS_AD >> AD, with a proportion mediated (prop.Med) of
34.84% (95% CI: 19.82%-83.43%); Obesity >> MetRS_VaD >>VaD, with a prop.Med of
31.91% (95% CI: 18.61%-70.26%). These mediating effects were largely preserved even
after additional adjustment for *APOE* ε4 carrier status.

When focusing on key MetRS metabolites, several metabolites—particularly glucose and
LA_pct—were identified as key mediators of the impact of modifiable risk factors such as
obesity, diabetes, hypertension, and education on dementia, with the strongest mediation
being observed for the effect of obesity on ACD and AD (**Supplementary Tables 11, 12,**
Figure 6). For example, glucose and LA_pct mediated over 30% of the association between
obesity and both ACD and VaD. However, when additionally adjusting for the remaining risk
factors, only glucose and LA_pct mediated over 10% of the effects—specifically, those of
obesity and smoking on VaD, and hypertension on AD. We also observed potential
suppression effects (defined as indirect effect acting in the opposite direction to total effect)
primarily in the relationship between obesity and ACD/VaD, predominantly mediated by
BCAAs and percentages of small LDL lipid components (**Supplementary Tables 11, 12,**
Supplementary Figure 13). As the association between modifiable risk factors and
metabolites were explored cross-sectionally, we also examined the reverse direction—
modifiable risk factors mediating the associations between metabolite levels and dementia.
These analyses showed stronger and more significant mediating effects (**Supplementary**

Table 11, 12). For example, we found evidence that diabetes strongly mediated the

association between higher glucose levels and all three types of dementia: (AD: prop.Med =

35.51%, 95% CI: 20.88%-73.65%), (VaD: 31.34%, 95% CI: 23.04%-43.57%), and (ACD:

28.75%, 95% CI: 19.45%-47.11%).

MR analyses

We first used MR analyses to assess the bidirectional causal relationships between key

MetRS metabolites and dementia subtypes, as well as with key neuroimaging phenotypes

(WMHs and WMHs related atrophy) used as VaD proxies. Six associations were found

significant (*pFDR*<0.1) (**Supplementary Table 13, Figure 7**). Overall, the strongest

association and the only significant at p*FDR*<0.05 was observed for glutamine, which

showed a significant inverse association with the risk of AD (β = -0.168, SE = 0.035, *pFDR* <

0.001). Other metabolites associated with AD included S_LDL_PL_pct and leucine

(*pFDR*<0.1). We also observed a positive causal link between LA_pct and valine with

WMHs-related atrophy. Finally, in the reverse direction, WMHs were causally associated

with increased LDL size. All MR associations showed consistent directional effects in

sensitivity analyses (MR-Egger, Weighted Median and Weighted Mode) (**Supplementary**

Table 14); however, only the associations of glutamine and leucine with AD, and of LA_pct

with WMHs were statistically significant using all three sensitivity methods. Scatter plots of

exposure-outcome tests are shown in **Supplementary Figure 14**. No pleiotropy (MR-Egger

intercept P□>0.05) was observed and although MR_PRESSO indicated pleiotropy in the

S_LDL_PL_pct-AD relationship, no outlier SNPs were detected and there was no significant

change in distortion (p>0.05 for both tests) (**Supplementary Table 15**). We aimed to

replicate the significant (p<0.05) MR associations using metabolite GWAS data from the UK

Biobank and the Estonian Biobank. Glutamine was significantly associated with a lower risk

of AD (β = -0.112, p = 0.004), and LA_pct showed a trend toward a positive association with

WMHs_atrophy (β = 0.065, p = 0.081) (**Supplementary Table 16**).

LOO analyses identified one SNP with a substantial influence on the combined effect

estimates for LA_pct (**Supplementary Table 17**). Removal of rs174528, located upstream of

the FADS1 gene in the FADS 1/2/3 cluster, resulted in complete attenuation of the causal

effect of LA_pct on WMHs_atrophy, indicating that the observed association was largely

driven by this individual variant. Subsequent colocalisation analyses on the +/- 250kb region

of rs174528 (Chr11:61293499-61793499) showed strong evidence of colocalisation between

LA_pct and WMHs_atrophy (**Supplementary Table 18**). Further statistical colocalisation

analyses were conducted between blood eQTLs at 6 genes at the chr11: 61293499-61793499

region, LA_pct and WHM_atrophy (**Supplementary Table 19**). Only eQTLs for fatty acid

desaturase 1 (*FADS1*) gene expression levels showed statistical colocalisation with LA_pct

(PP.H4 = 0.95) and with WMH_atrophy (PP.H4 = 0.84) (**Supplementary Figure 15**).

Suggestive colocalisation was observed between *FADS2* and *TMEM258* with WMHs_atrophy

(PP.H4 = 0.76 and 0.65, respectively). MR analyses highlighted that higher *FADS1*

expression was causally associated with increased LA_pct (β = 0.51, 95% CI: 0.255-0.765, p

$< 1 \times 10^{2}$) (Wald ratio; using rs174528 as IV) and with WMHs_atrophy (β = 0.856, 95%

CI: 0.813-0.899, p = 1.21×10) (Wald ratio; using rs174528 as IV). Causal mediation

analysis subsequently showed that LA_pct partially mediated the effect of *FADS1* on

WMHs_atrophy (proportion mediated [95% CI] = 6.63%, 1.41-11.86%).

In addition, based on our previous work that highlighted rs2939302 as an influential SNP [9]

and a very recent AD GWAS study [47] reporting a novel AD SNP - rs2657879- which is in

perfect LD with rs2939302 (R^2=1, https://ldlink.nih.gov/), we further investigated whether

exclusion of rs2939302 attenuated the causal effect of glutamine on AD. LOO analysis

highlighted that removal of rs2939302 resulted in a 17.7% change in the beta estimate,

highlighting partial attenuation of the causal effect of glutamine on AD (**Supplementary**

Table 17). Subsequent colocalisation analyses (+/- 250kb region of rs2939302

(Chr12:56610020-57110020)) showed strong evidence of colocalisation between glutamine

and AD (PP.H$_4$ ≥ 0.8) (**Supplementary Table 18**). Further statistical colocalisation

analyses were conducted between blood eQTL for 5 genes at the chr12: 56610020-57110020

region, glutamine and AD (**Supplementary Table 19**). Only SPRY domain-containing

protein 4 (*SPRYD4*) showed statistical colocalization with glutamine (PP.H4 = 0.97) and

with AD (PP.H4 = 0.82) (**Supplementary Figure 16**). MR analyses further showed that

SPRYD4 expression showed positive causal associations with glutamine (β = -0.279, 95% CI:

-0.159 - -0.399, p = 5.64×10) and with AD (β = 0.088, 95% CI: 0.023-0.153, p = 0.007)

and that glutamine causally mediated the effect of blood *SPRYD4* expression on AD

(proportion mediated [95% CI] = 53.20%, 3.22-103.17%).

MR mediation analyses between metabolites, modifiable risk factors and dementia

To complement observational analyses and strengthen causal inference, we additionally

conducted mediation MR analyses to explore whether key causal metabolites mediate the

effect of risk factors (RF) on dementia (RF >>metabolites >> dementia) or conversely,
whether RFs mediate the effect of key metabolites on dementia (metabolites >> RF >>
dementia), using a causal mediation framework. The causal framework included the
following pathways: RF>>metabolites, RF>>dementia, and metabolites>>RF. Results are
displayed in **Supplementary Table 20.** We identified 65 significant associations (*pFDR* <
0.1), all of which remained robust after outlier correction using MR-PRESSO. LOO did not
find single influential SNPs (**Supplementary Tables 21-23**).

For RF>>dementia, we found that greater educational attainment was causally associated
with decreased AD risk, whereas higher DBP, SBP, and hypertension were significantly
associated increased risk of VaD (**Supplementary Table 23**). No significant associations
were observed between modifiable risk factors and ACD. For RF >> metabolites, educational
attainment and BMI were associated with glutamine levels, while both diabetes and BMI
were associated with leucine levels. For metabolites>>RFs, glucose, histidine, leucine, and
XXL_VLDL_L levels were associated with SBP, DBP and hypertension (**Supplementary
Table 24**). Subsequent causal mediation analyses showed that glutamine significantly
mediated the association between education and AD (**Figure 7, Supplementary Table 24**).
When looking at mediation effects of metabolites >> RF >> dementia, hypertension and
elevated blood pressure significantly mediated the effects of several metabolites—histidine
and leucine—on the risk of VaD, despite the absence of a direct causal association between
these metabolites and VaD (**Supplementary Table 24**).

Discussion

In this large-scale, systematic analysis, we identified sparse plasma metabolomic signatures
that predicted incident dementia—specifically AD, VaD and ACD—and which improved risk
stratification beyond established clinical risk factors. Several key metabolites were strongly
associated with brain volumetric measures and substantially mediated the effects of
modifiable risk factors on dementia outcomes. Causal inference analyses highlighted that a
subset of metabolites showed evidence of causal associations with AD and WMH-related
atrophy, used as a proxy of VaD [38], with glutamine additionally partially mediating the effect
of educational attainment on AD risk. By integrating results from both observational analyses
and MR, our study provides evidence implicating early metabolic dysregulation in the
pathogenesis of dementia, with potentially important implications for risk stratification and
targeted prevention strategies.

LA_pct—identified as a shared protective metabolite across all three MetRS—was
consistently associated with larger brain volumes, lower WMH atrophy, and lower future
dementia risk; and appeared to mediate the effect of modifiable risk factors, particularly
obesity, on dementia in our observational analyses using the UKB. LA is an essential nutrient
since it cannot be synthesised in the body. As the most abundant omega-6 fatty acids, it plays
a fundamental role in maintaining cell membrane integrity, which is crucial for healthy
neuronal function [48]. Although this pattern was not fully supported by cross-sectional
associations in the ANM/DCR cohort, and when looking at the positive association between
LA_pct and NfL and GFAP levels, it is consistent with our previous finding that higher
LA_pct relates to better cognitive function in late midlife (NSHD)[49] and with broader
epidemiological evidence linking higher LA levels to improved cardiometabolic health,
including lower cardiovascular disease and type 2 diabetes risk[50].

Conversely, our MR analyses suggested that higher LA_pct levels were causally linked to
greater WMHs_atrophy, but that this association is driven by genetic variation at the
FADS1/2/3 locus. Statistical colocalisation, blood eQTL integration and MR-based mediation
further suggested that genetically predicted LA_pct levels (instrumented by rs174528)
partially mediate the effect of blood *FADS1* gene expression on WMHs_atrophy.
The *FADS1/2/3* cluster is a pleiotropic locus, and SNPs in this region - such as rs174528 - are
known to play a critical role in the regulation numerous polyunsaturated fatty acids (PUFAs)
-and other lipid fractions- and are responsible for the desaturation of omega-6 PUFAs in the
LA to AA pathway, as well as omega-3 PUFAs in the alpha-linolenic to docosahexaenoic acid
pathway [51]. Our previous MR analyses on the causal effects of metabolites on
neuropsychiatric traits using the Metabolon platform also suggested that higher levels of LA-
containing lipids were linked to increased risk of depression, anxiety, bipolar disorder and
schizophrenia, whilst Arachidonic Acid (AA)-containing lipids had overall protective effects
[9]; a finding also observed in an independent study on bipolar disorder, suggesting that the
conversion of LA into AA by the FADS1/2/3 cluster genes may play a key role in the
observed associations and ultimately in brain pathology [51]. AA was not measured in the
Nightingale platform, but we examined other PUFAs, with both omega_3_pct and
DHA_3_pct showing significantly negative associations with WMHs_atrophy. LOO analyses
suggested that these associations also appear to be driven by genetic variation at the
FADS1/2/3 locus and specifically rs174528, but in the opposite direction compared to

LA_pct (**Supplementary Figure 17**). These findings further support the involvement of the

FADS1/2/3 cluster gene variation in PUFA metabolism, brain health and neurodegeneration.

Although liver is the main organ of PUFA metabolism, the *FADS1/2/3* cluster genes are

expressed widely across human tissues and cell types, including in the brain [52], and genetic

variation at the FADS1/2/3 locus has been associated with several brain imaging-derived

phenotypes [53,54]. As PUFAs can also be transported into the brain across the blood-brain

barrier it is therefore possible that LA_pct and overall PUFAs can impact white matter

atrophy via both peripheral and brain specific mechanisms. However, although variants at

the FADS1/2/3 locus are biologically credible instruments because of their direct role in

PUFA biosynthesis, their pleiotropic nature means they may violate core MR assumptions

and may not be credible instruments[55]. Nevertheless, the statistical colocalisation between

FADS1 expression, LA_pct and WMH_atrophy implicates altered PUFA metabolism as a

mechanism linking genetic variation at this locus to WMHs_atrophy.

Overall, our findings highlight that genetic variation in fatty acid metabolism may have a

detrimental effect on white matter integrity, at least partly through altered LA_pct and other

PUFAs, while higher circulating LA_pct — potentially reflecting a healthier diet — is

associated with healthier brain structure and lower dementia risk. Together, these results

position LA_pct and related PUFA pathways as key mediators linking genetic risk, diet,

modifiable risk factors and dementia-related brain changes, highlighting their potential both

for prevention and for therapeutic targeting. Further work is urgently needed to disentangle

these effects.

Glutamine levels showed the strongest evidence for a protective causal association with risk

of AD in our MR analyses, and this result was further validated using IVs from a larger

GWAS. This finding is consistent with our previous MR studies using smaller GWAS

datasets for glutamine and AD [5], as well as with our recent work where glutamine was

measured using the Metabolon platform [9]. Our cross-sectional analyses with imaging

phenotypes also showed that higher glutamine levels were associated with favourable brain

structural measures, suggesting a potential direct neuroprotective effect, in agreement with

our MR results. Our observational analysis using the UKB produced more mixed results,

showing that elevated blood glutamine levels were nominally associated with a decreased risk

for incident VaD and decreased NfL levels-in agreement with the MR results- but on the other

hand they were also nominally associated with increased risk of AD — the latter finding

being validated using the independent ANM/DCR dataset. These contradictory results with

MR may reflect reverse causation or residual confounding common in observational analyses.

Further MR sensitivity analyses using leave-one-out MR, showed that excluding rs2939302

located on 12q13.3, near the Glutaminase 2 gene (*GLS2)*, partially attenuated the causal

relationship between glutamine and AD, and statistical colocalisation supported a shared

signal among glutamine, blood *SPRYD4* expression levels, and AD. Further MR mediation

suggested that glutamine mediated the association between *SPRYD4* gene expression and AD

- consistent with a non-significant trend observed in our previous study using the Metabolon

platform [9]. These findings are supported by a recent GWAS study [47] reporting a novel AD

SNP - rs2657879- in perfect LD with rs2939302 (R2=1, https://ldlink.nih.gov/) and which

colocalised with *SPRYD4* expression in other tissues and cell types, like microglia, inhibitory

neuron, spinal cord and macrophage.   *SPRYD4* is located in the 12q13.3 locus, upstream of

GLS2, and higher *SPRYD4* levels have been shown to inhibit cancer growth through

apoptotic mechanisms [56]. *GLS2*-encoding a liver-expressed glutaminase 2 required for

hydrolysis of glutamine to glutamate- is the most biologically plausible candidate for the

observed associations. Nevertheless, our analyses did not support a shared causal variant

between *GLS2* and glutamine (PP4 = 3.97E-7) or between *GLS2* and AD (PP4=0.42), but

indicated that *GLS2* and glutamine in this region are highly likely to be driven by

independent causal variants (PP3=1), a finding in agreement with our previous work [9].

Additionally, in the recently published AD GWAS[47] only brain and not blood *GLS2* levels

colocalised with AD [47]. Future work investigating tissue-specific (brain vs blood) eQTLs,

single-cell colocalization, and fine-mapping at 12q13.3 will be crucial to disentangle

SPRYD4 from *GLS2*, define the cell types mediating risk, and prioritize targets along the

glutamine-glutamate axis.

Finally, our MR mediation analysis found that glutamine causally mediated the protective

relationship between education and AD risk. Higher education is associated with greater

cognitive and synaptic reserve. Glutamine plays a critical role in neurotransmitter cycling,

serving as a precursor for glutamate and GABA, which are essential for synaptic transmission

and plasticity. Higher education may therefore enhance glutamine metabolism to support

these synaptic functions, thereby contributing to cognitive resilience. Taken together, our data

implicate glutamine at the intersection of genetic susceptibility and modifiable risk,

underscoring a plausible protective role in AD and the need for future mechanistic

investigation.

BCAAs are essential amino acids that constitute approximately one-third of the total amino
acid content in the human body [57]. They are involved in critical cellular processes, including
glutamate metabolism, protein synthesis, and energy production in the brain [58]. Several
observational studies—including ours—suggest that higher BCAA levels are associated with
a reduced risk of dementia [59]. However, experimental evidence from transgenic mouse
models of AD has shown that lowering BCAA levels can alleviate AD-related pathology and
cognitive decline. Furthermore, BCAAs have been implicated in promoting tau
phosphorylation through the activation of the mTOR signalling pathway [60]. Our MR study
also identified leucine as a risk factor of AD in contrast to our observational analyses but
consistent with findings from an independent MR study [61]. When we investigated this
relationship further using restricted cubic spline models, they revealed a non-linear (U-shaped
or J-shaped) relationship between BCAAs (including leucine, valine and total BCAAs) and
dementia subtypes (**Supplementary Figure 18**), suggesting that while moderate levels may
be protective, excessively high levels could potentially be associated with increased dementia
risk. These findings highlight the dual nature of BCAAs and emphasise the importance of
maintaining a balanced BCAA level for brain health.

S_LDL_PL_pct and LDL_size were the only two metabolites demonstrating relatively
consistent associations across individual Cox analyses, neuroimaging measures, and MR
analyses, although the MR findings lacked robustness. S_LDL_PL_pct was associated with
increased risk of dementia, reduced brain volume, and showed a causal relationship with
higher AD risk. In contrast, LDL_size exhibited inverse associations. Interestingly, although
S_LDL_PL_pct appears detrimental to brain health, it was linked to smaller WMHs. One
possible explanation is that altered phospholipid content in small LDL particles reflects
changes in lipid metabolism or inflammation [62] and impair neuronal or synaptic health [63],
contributing to neurodegeneration and dementia risk independent of vascular injury.
Supporting this, S_LDL_PL_pct was absent from the VaD metabolomic signature.
Furthermore, S_LDL_PL_pct correlated with global grey matter and hippocampal volumes,
but not with global white matter volume, suggesting a specific effect on neuronal and
synaptic integrity. In contrast, LDL_size was primarily associated with VaD but not AD,
linked to white matter volume and WMHs but not to global grey matter or hippocampal
volume, indicating a predominantly vascular pathway in dementia risk. Taken together, these
distinct patterns suggest that S_LDL_PL_pct influences dementia risk mainly through

neurodegenerative mechanisms, whereas LDL_size could potentially contribute primarily via

vascular pathways.

Beyond metabolomic signatures, we also found that a higher percentage of FC/TC in larger

HDL particles is associated with an increased risk of dementia, whereas a higher percentage

in smaller HDL particles appears protective—an observation not reported in previous studies.

HDL particles absorb the active form of cholesterol-FC from peripheral tissues, initially

forming small HDL particles that mature into larger HDL as FC is esterified into store form

of cholesterol-CE within the particle, enabling cholesterol transport to the liver [64]. However,

an excess of FC in large HDL particles can lead to reverse diffusion of cholesterol back into

peripheral cells [65], potentially indicating HDL dysfunction. In contrast, smaller HDL

particles are more actively involved in cholesterol uptake from tissues, so a higher FC ratio in

these particles may reflect more efficient cholesterol clearance. Supporting our results, a

recent study also observed high HDL FC content resulting in greater influx into macrophages

[66], reinforcing the role of high HDL FC content in larger HDL as a marker of HDL

dysfunction. Taken together, our findings suggest that the detailed lipid composition of

specific lipoprotein subfractions may offer more precise insights into the mechanisms

underlying dementia and serve as early dementia indicators.

Additionally, we also investigated the effect of sex and *APOE* ε4 on the relationship between

metabolites and dementia, given their strong links with both metabolites and dementia [67]. We

found that protective effects of most metabolites against dementia were attenuated in *APOE*

ε4 carriers or females. For example, PUFA ratio in all fatty acids including omega-3_pct and

omega-6_pct appears to be less protective against dementia in females, consistent with our

recent study showing that female participants with AD had reduced levels of highly

unsaturated fatty acids[7] measured using LC-MS. Collectively, our results highlight that both

APOE ε4 carrier status and sex shape how metabolites influence dementia risk, often

reducing the protective benefits and altering harmful impacts, suggesting personalised

approaches may be needed for prevention or treatment.

Our study has several limitations. First, the UK Biobank cohort is generally healthier than the

general population, with participants more likely to be free of major diseases and adverse

health behaviours [68]. As a result, plasma metabolite levels in this cohort may be skewed

toward a healthier profile, potentially underrepresenting individuals with metabolite

imbalances that are detrimental to brain health. Despite this, we still observed U-shaped

associations for several key metabolites, suggesting that even within a healthier population, higher or lower extremes of these metabolites may be associated with increased dementia risk. Second, we did not investigate the influence of lifestyle factors such as diet and physical activity on metabolite levels due to substantial missing data for these variables in the UK Biobank. Nevertheless, future studies in cohorts with more comprehensive lifestyle data are warranted to explore how these modifiable behaviours impact metabolomic profiles and dementia risk. Third, due to the current limitations of metabolite GWAS, we were unable to obtain summary statistics for all key metabolites—particularly for total BCAAs and metabolite ratios—which restricted our MR analyses. Finally, plasma metabolites may not fully reflect central nervous system metabolism or brain-specific pathological processes. Although peripheral metabolic changes can provide valuable insights, they may not directly capture the metabolic environment within the brain. Future research integrating CSF metabolomics or brain imaging-derived metabolic markers could help address this limitation.

Conclusion

In this large-scale metabolomic study, integrating machine learning with causal inference approaches, we identified robust metabolic signatures predictive of dementia subtypes beyond conventional risk factors. Key metabolites—including LA_pct, glutamine, BCAAs, S_LDL_PL_pct, and LDL_size—were associated with structural brain changes, influenced the effects of established lifestyle risk factors (particularly obesity, with this effect strongly mediated by LA_pct), and showed evidence for causal involvement in dementia. These findings highlight metabolic dysregulation as an early, potentially modifiable contributor to dementia pathogenesis and suggest that blood metabolites may serve as valuable biomarkers for risk stratification, mechanistic insight, and targeted prevention strategies.

Data availability

The data that support the findings of this study are available from the UK Biobank project site, subject to the registration and application process. Further details can be found at https://www.ukbiobank.ac.uk.

Code availability

The code used in this study analysis code will be made available at https://github.com/Wolfson-PNU-QMUL/.

760   **Acknowledgements**

761   We are grateful to the participants of the UK Biobank. The National Health Service (NHS)

762   North West Centre for Research Ethics Committee approved the UK Biobank study

763   (reference 11/NW/0382), which conforms to the provisions of the Declaration of Helsinki.

764   We also thank the High Performance Computing cluster (Apocrita) at QMUL for facilitating

765   these analyses, and all members of the Centre for Preventive Neurology for their ongoing

766   support. The Centre for Preventive Neurology is supported by a grant from Barts Charity.

767   This work was also supported by Alzheimer's Research UK (SRF-2016A-3) and Parkinson's

768   UK (G2403). We acknowledge the participants and investigators of the FinnGen study

769   (https://www.finngen.fi/en/access_results) for their contributions.

1.	Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet* 2024; **404**(10452): 572-628.

2.	Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. *The Lancet* 2021; **397**(10284): 1577-90.

3.	Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. *N Engl J Med* 2021; **384**(18): 1691-704.

4.	Zeng BS, Tseng PT, Liang CS. Lecanemab in Early Alzheimer's Disease. *N Engl J Med* 2023; **388**(17): 1630.

5.	Lord J, Green R, Choi SW, et al. Disentangling Independent and Mediated Causal Relationships Between Blood Metabolites, Cognitive Factors, and Alzheimer's Disease. *Biol Psychiatry Glob Open Sci* 2022; **2**(2): 167-79.

6.	Ardanaz CG, Ramirez MJ, Solas M. Brain Metabolic Alterations in Alzheimer's Disease. *Int J Mol Sci* 2022; **23**(7).

7.	Wretlind A, Xu J, Chen W, et al. Lipid profiling reveals unsaturated lipid reduction in women with Alzheimer's disease. *Alzheimers Dement* 2025; **21**(8): e70512.

8.	Proitsi P, Kim M, Whiley L, et al. Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. *Alzheimers Dement* 2017; **13**(2): 140-51.

9.	Gilchrist L, Mutz J, Hysi P, et al. Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders. *BMC Med* 2025; **23**(1): 326.

10.	Green RE, Lord J, Scelsi MA, et al. Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease. *Alzheimer's Research and Therapy* 2023; **15**(1).

11.	Morze J, Wittenbecher C, Schwingshackl L, et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. *Diabetes Care* 2022; **45**(4): 1013-24.

12.	Langenau J, Boeing H, Bergmann MM, Nothlings U, Oluwagbemigun K. The Association between Alcohol Consumption and Serum Metabolites and the Modifying Effect of Smoking. *Nutrients* 2019; **11**(10).

13.	Guo J, Jia P, Gu Z, et al. Altered gut microbiota and metabolite profiles provide clues in understanding resistant hypertension. *J Hypertens* 2024; **42**(7): 1212-25.

14.	Al-Sulaiti H, Diboun I, Agha MV, et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. *J Transl Med* 2019; **17**(1): 348.

15.	Robinson O, Carter AR, Ala-Korpela M, et al. Metabolic profiles of socio-economic position: a multi-cohort analysis. *Int J Epidemiol* 2021; **50**(3): 768-82.

16.	Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; **12**(3): e1001779.

17.	Julkunen H, Cichońska A, Tiainen M, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. *Nature Communications* 2023; **14**(1).

18.	Ritchie SC, Surendran P, Karthikeyan S, et al. Quality control and removal of technical variation of NMR metabolic biomarker data in ~120,000 UK Biobank participants. *Scientific Data* 2023; **10**(1).

19.   Biondo F, Jewell A, Pritchard M, et al. Brain-age is associated with progression to dementia in memory clinic patients. *Neuroimage Clin* 2022; **36**: 103175.

20.   Kuhn M. Building Predictive Models in R Using the caret Package. *Journal of Statistical Software* 2008; **28**(5): 1 - 26.

21.   Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J Stat Softw* 2010; **33**(1): 1-22.

22.   Lovestone S, Francis P, Kloszewska I, et al. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. *Ann N Y Acad Sci* 2009; **1180**: 36-46.

23.   Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001; **58**(12): 1985-92.

24.   Simren J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimers Dement* 2021; **17**(7): 1145-56.

25.   MacKinnon DP, Fairchild Aj Fau - Fritz MS, Fritz MS. Mediation analysis. (0066-4308 (Print)).

26.   Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet* 2021; **53**(9): 1276-82.

27.   Lumsden AL, Mulugeta A, Zhou A, Hypponen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. *EBioMedicine* 2020; **59**: 102954.

28.   Karjalainen MK, Karthikeyan S, Oliver-Williams C, et al. Genome-wide characterization of circulating metabolic biomarkers. *Nature* 2024; **628**(8006): 130-8.

29.   Tambets R, Kronberg J, van der Graaf A, et al. Genome-wide association study for circulating metabolic traits in 619,372 individuals. *medRxiv* 2025: 2024.10.15.24315557.

30.   Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. *Hum Mol Genet* 2018; **27**(20): 3641-9.

31.   Okbay A, Wu Y, Wang N, et al. Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. *Nat Genet* 2022; **54**(4): 437-49.

32.   Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. *Nat Genet* 2021; **53**(11): 1616-21.

33.   Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* 2018; **50**(10): 1412-25.

34.   Donertas HM, Fabian DK, Valenzuela MF, Partridge L, Thornton JM. Common genetic associations between age-related diseases. *Nat Aging* 2021; **1**(4): 400-12.

35.   Saunders GRB, Wang X, Chen F, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. *Nature* 2022; **612**(7941): 720-4.

36.   Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet* 2018; **50**(11): 1505-13.

37.   Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res* 2019; **4**: 186.

38.   Patel Y, Shin J, Sliz E, et al. Genetic risk factors underlying white matter hyperintensities and cortical atrophy. *Nat Commun* 2024; **15**(1): 9517.

39.   Jiang D, Hou J, Nan H, et al. Relationship between hearing impairment and dementia and cognitive function: a Mendelian randomization study. *Alzheimers Res Ther* 2024; **16**(1): 215.

40.   Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016; **40**(4): 304-14.

41.   Ooi BNS, Loh H, Ho PJ, et al. The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. *Int J Epidemiol* 2019; **48**(3): 781-94.

42.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015; **44**(2): 512-25.

43.   Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018; **50**(5): 693-8.

44.   Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* 2014; **10**(5): e1004383.

45.   Yoshiji S, Butler-Laporte G, Lu T, et al. Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* 2023; **5**(2): 248-64.

46.   Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat Med* 2021; **40**(25): 5434-52.

47.   Uffelmann E, Wightman DP, Bahrami S, et al. Genomic analyses reveal new insights into Alzheimer's disease. *medRxiv* 2025: 2025.10.10.25337470.

48.   Whelan J, Fritsche K. Linoleic acid. (2156-5376 (Electronic)).

49.   Proitsi P, Kuh D, Wong A, et al. Lifetime cognition and late midlife blood metabolites: findings from a British birth cohort. *Transl Psychiatry* 2018; **8**(1): 203.

50.   Jackson KH, Harris WS, Belury MA, Kris-Etherton PM, Calder PC. Beneficial effects of linoleic acid on cardiometabolic health: an update. *Lipids Health Dis* 2024; **23**(1): 296.

51.   Stacey D, Benyamin B, Lee SH, Hypponen E. A Metabolome-Wide Mendelian Randomization Study Identifies Dysregulated Arachidonic Acid Synthesis as a Potential Causal Risk Factor for Bipolar Disorder. *Biol Psychiatry* 2024; **96**(6): 455-62.

52.   Reynolds LM, Howard TD, Ruczinski I, et al. Tissue-specific impact of FADS cluster variants on FADS1 and FADS2 gene expression. *PLoS One* 2018; **13**(3): e0194610.

53.   Shadrin AA, Kaufmann T, van der Meer D, et al. Vertex-wise multivariate genome-wide association study identifies 780 unique genetic loci associated with cortical morphology. *Neuroimage* 2021; **244**: 118603.

54.   van der Meer D, Frei O, Kaufmann T, et al. Understanding the genetic determinants of the brain with MOSTest. *Nat Commun* 2020; **11**(1): 3512.

55.   Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. *BMC Med* 2022; **20**(1): 210.

56.   Zahid KR, Han S, Zhou F, Raza U. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death. *Cell Oncol (Dordr)* 2019; **42**(1): 55-66.

57.   Polis B, Samson AO. Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders. *Neural Regen Res* 2020; **15**(8): 1460-70.

58.   Choi BH, Hyun S, Koo S-H. The role of BCAA metabolism in metabolic health and disease. *Experimental & Molecular Medicine* 2024; **56**(7): 1552-9.

59.   Fu Y, Wang Y, Ren H, Guo X, Han L. Branched-chain amino acids and the risks of dementia, Alzheimer's disease, and Parkinson's disease. *Front Aging Neurosci* 2024; **16**: 1369493.

60.   Amin N, Liu J, Bonnechere B, et al. Interplay of Metabolome and Gut Microbiome in Individuals with Major Depressive Disorder vs Control Individuals. *JAMA Psychiatry* 2023; **80**(6): 597-609.

61.   Qian XH, Liu XL, Zhang B, et al. Investigating the causal association between branched-chain amino acids and Alzheimer's disease: A bidirectional Mendelian randomized study. *Front Nutr* 2023; **10**: 1103303.

62.   Que X, Hung MY, Yeang C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. *Nature* 2018; **558**(7709): 301-6.

63.   Kim HY, Huang BX, Spector AA. Phosphatidylserine in the brain: metabolism and function. *Prog Lipid Res* 2014; **56**: 1-18.

64.   Chiesa ST, Charakida M. High-Density Lipoprotein Function and Dysfunction in Health and Disease. *Cardiovasc Drugs Ther* 2019; **33**(2): 207-19.

65.   Pownall HJ, Rosales C, Gillard BK, Gotto AM, Jr. High-density lipoproteins, reverse cholesterol transport and atherogenesis. *Nat Rev Cardiol* 2021; **18**(10): 712-23.

66.   Yelamanchili D, Gillard BK, Gotto AM, Jr., et al. HDL-free cholesterol influx into macrophages and transfer to LDL correlate with HDL-free cholesterol content. *J Lipid Res* 2025; **66**(1): 100707.

67.   Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. *Neurology* 2017; **89**(13): 1382-90.

68.   Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* 2017; **186**(9): 1026-34.

Figure 1. Flowchart

Participants were selected from the UK Biobank and Nightingale Health NMR datasets. Individuals with prevalent dementia, early-onset dementia (age < 60), missing *APOE* ε4 genotype data, or more than 20% missing metabolite values were excluded, resulting in a final sample size of 269,284. Individual Cox proportional hazards (PH) models were used to assess associations between metabolites and incident dementia subtypes: all-cause dementia, Alzheimer's disease, and vascular dementia. A subsequent LASSO-regularised Cox PH model identified metabolomic signatures and key metabolites associated with each dementia subtype in the non-neuroimaging subset. Key metabolites were further examined for their mediating roles between modifiable risk factors and dementia in the whole dataset, and their associations with neuroimaging phenotypes in a separate imaging subset. Finally, Mendelian randomisation (MR) and multivariable MR analyses were conducted to explore causal relationships between key metabolites and dementia outcomes, as well as their potential causal mediation between modifiable risk factors and dementia.

Figure 2. Predictive performance of the metabolomic signatures

Figures (top): Comparison of prediction performance of dementia subtypes (All-cause dementia (ACD), Alzheimer's Disease (AD), and Vascular dementia (VaD)) using COX PH models trained on the metabolomic risk score only, Age+Sex, *APOE* ε4 status and dementia risk factors, and the sets' combinations with the metabolomic risk score. Horizontal dashed lines indicate the median performance of the three clinical predictor sets.

Figure (bottom): Incremental prediction performance by adding the metabolomic risk score to the model 1 (green), model 2 (red), and model 3 (purple).

Model 1 adjusted for age, sex, ethnicity, Townsend index, centre, model 2 additionally adjusted for APOE ε4 carrier status, model 3 additionally adjusted for education level, obesity, smoking, alcohol, history of hypertension and diabetes.

Figure 3. Venn diagram of metabolomic signatures of All-cause dementia (ACD), Alzheimer's disease (AD) and Vascular dementia (VaD).

Red color: positive association; Blue color: negative association.

Figure 4. Associations between metabolomic risk scores (MetRS), key metabolites, and global brain metrics including brain volumes and brain age.

Models were adjusted for age, sex, ethnicity, Townsend deprivation index, assessment centre, and *APOE* ε4 carrier status.

[+] p<0.05 and FDR>0.05, * FDR<0.05, ** FDR<0.01, ***FDR<0.001

Figure 5. Association between dementia-subtype metabolomic risk scores (MetRS) and regional brain volumes.

Dementia subtypes include all-cause dementia (ACD), Alzheimer's disease (AD), and vascular dementia (VaD). Only statistically significant associations (FDR < 0.05) are displayed. Red regions indicate positive associations, while blue regions indicate negative associations. Non-significant results are shown as blank.

Models were adjusted for age, sex, ethnicity, Townsend deprivation index, assessment centre, and *APOE* ε4 carrier status.

Figure 6. Mediating effects of metabolomic signatures in the relationship between modifiable risk factors and dementia subtypes: all-cause dementia (ACD), Alzheimer's disease (AD), and vascular dementia (VaD).

Left: Each diagram displays pathways from modifiable risk factors (left panel), through key metabolites (middle panel), to dementia outcomes (right panel), only those with proportion of mediation (Prop.med) >10% are shown in diagrams.
Right: Mediation path diagram highlighting the strongest effects (Prop.med >30%).
Model 1: adjusted for age, sex, ethnicity, Townsend deprivation index and assessment centre; Model 2 additionally adjusted for *APOE* ε4 carrier status.

Figure 7. Mendelian randomisation (MR) and mediation MR.

Top: Causal associations between key metabolites and dementia and related outcomes: all-cause dementia (ACD), Alzheimer's disease (AD), and vascular dementia (VaD), white matter hyperintensities (WMHs), WMHs related brain atrophy (WMHs_atrophy).

Bottom: Mediation path diagram showing significant causal mediating effects of key metabolites in the relationships between risk factors and dementia.